NOVAVAX INC
NVAXNASDAQTrading Snapshot
- Day Range
- $10.19 – $10.62
- 52-Week Range
- $6.20 – $13.39
- Volume (shares)
- 2,788,557
- Avg Volume (shares)
- —
- Shares Outstanding
- 164.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $1.12B
- Last Q Revenue
- $57M
- P/E Ratio
- -6.9
- P/S Ratio
- 4.2x
- EPS (TTM)
- $-1.51
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +8.0%
NOVAVAX INC
NVAX
StockOtter · stockotter.spaceAbout NOVAVAX INC
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Th
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock sta
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.